Introduction
Treatment with high dose melphalan followed by autologous stem cell infusion (ASCT) has improved survival in patients with multiple myeloma [1] [2] [3] [4] and remains gold standard for younger patients even in the era of new drugs 4 . In a previous study, we showed that a reduced initial therapy induced less toxicity but with no reduction in treatment efficacy. 5 Building on these results, we now aimed to explore if consolidation therapy after ASCT could improve treatment results. The proteasome inhibitor bortezomib has proven to be very efficient as relapse treatment also for patients who have previously undergone ASCT. 6 In this open, multicenter phase III randomized trial we compared the effect of bortezomib consolidation initiated three months after ASCT with no consolidation, which was standard procedure within the Nordic countries at the time of the study start. Importantly, patients included in this trial did not receive bortezomib as part of induction therapy. The primary objective of the study was to determine whether the addition of bortezomib consolidation would improve progression-free survival (PFS).
Knowing that many patients have a high quality of life (QoL) during the first period of disease control 7 and that consolidation might interfere with this we also focused on toxicity and QoL during the study period.
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From
Methods

Study design and patients
The study was undertaken at 23 Apr 2010 when the last randomized patient had been followed for 12 months. An extra update for overall survival was performed Apr 2011. The primary endpoint was PFS and secondary endpoints were response rate, overall survival, quality of life and tolerability.
Myeloma patients with newly diagnosed symptomatic and measurable disease were eligible for inclusion in this trial. All patients had received initial therapy followed by stem cell collection and ASCT. The regimen used for initial therapy was not mandated. However, the patients had to be bortezomib naïve at time of inclusion. The most common initial treatment was Cy-Dex (cyclophosphamide and high dose steroids), used for 169 out of 183 in the control group and 161 out of 187 in the consolidation group. Eight patients in both groups received a combination of thalidomide and steroids and the remaining patients received VAD or similar combinations. Patients were included at the time of ASCT but randomized three months later.
Exclusion criteria were neuropathy > grade 2 according to National Cancer Institute Common Toxicity Criteria (NCI CTC), severe heart disease including myocardial infarction within 6 months before enrolment, heart failure, New York Heart Association (NYHA) ≥ Class III or cardiac amyloidosis, history of hypotension or previous exposure to bortezomib.
All patients signed a written informed consent before inclusion. The study was approved by the ethical committees and health authorities in all participating countries and conducted in accordance with the Helsinki declaration of 1975 and the Guidelines for Good Clinical Practice. This study was registered at www.clinicaltrials.gov as #NCT00417911. 
Randomization
Patients were randomly assigned in a 1:1 ratio three months after ASCT to receive 20 doses of bortezomib during 21 weeks starting no later than within two weeks after randomization or to no further treatment. Stratification factors were age (< 60 years vs. ≥ 60) and single vs. double ASCT. The clinical investigators at each site called the research unit at Lunds University Hospital where randomization was performed using a computerized system.
Consolidation therapy
Bortezomib was given as single drug intravenously in six cycles. In the first two cycles, bortezomib was given twice weekly, day 1, 4, 8 and 11 in a 3 weeks schedule followed by four cycles in which bortezomib was given once weekly day 1, 8 and 15 in a four weeks schedule. Starting dose was 1.3 mg/m 2 but subsequent doses could be reduced due to neuropathy and/or haematological toxicity according to the standard pre-specified dosemodification algorithm. No doses were postponed. If a dose due to any cause could not be administered, it was reported as reduced to zero. In total, a maximum of 20 doses were given during 21 weeks. No corticosteroids, apart from a dose equivalent to less than prednisone 50 mg daily for no more than one week due to other medical conditions, or any other antineoplastic drugs were allowed. A total of six patients, one control and five bortezomib treated patients did receive steroids. Three due to chronic obstructive lung disease and one each for vasculitis, haemolytic anemia and high fever. In one case the dose was higher than permitted and that patient was censored at the time of start of steroid treatment.
Bisphosphonates were administered according to national guidelines. 
Follow-up evaluation
All patients were evaluated with serum and urine electrophoresis monthly for the first year and then every second month until disease progression. A bone marrow examination needed to be done to confirm CR. All data were reviewed according to Good Clinical Practice (GCP) criteria by an independent academic contract research organisation. After disease progression patients were followed for survival. Survival time was measured from randomization i.e. 3 months after ASCT until disease progression or death from any cause (PFS) or death from any cause (OS).
Health-related quality of life
Health-related quality of life (HRQOL) was assessed prospectively by use of the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTC QLQ-C30, version 3.0). 12 Scoring of the EORTC QLQ-C30 was performed according to published methods. 13 The questionnaire has previously been shown to be reliable and valid for myeloma patients.
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The questionnaires were filled in at baseline (time of randomization), at 8 weeks after randomization, and then every three months until two years and every six months until 3.5 years. The baseline questionnaires were administered by a physician or nurse and were filled in by the patients before randomization. The subsequent sets of questionnaires were mailed to the patient's homes with a stamped returned envelope.
Statistical analysis
The hypothesis of this study was that consolidation treatment with bortezomib would prolong median PFS with 12 months. To prove this with a power of 80 % and a significance level of 5 % (two-sided test), 396 patients needed to be included of whom at least 80 % would be randomized, that is at least 159 patients per arm.
The proportions of patients with a given characteristic were compared using Fisher's exact test for variables with frequency scale and Mann-Whitney U test for the remaining variables.
A Mann-Whitney U test was also used to calculate the significance of differences in the EORTC QLQ-C30 score between the control group and bortezomib group. Based on a previous work in myeloma patients, the minimal important difference in a HRQOL scale score was classified as a difference of at least 6 points (0-100 scale). 15 PFS and OS rates were calculated according to the Kaplan-Meier method, and survival comparisons between groups were made by the Log-Rank Test. PFS and survival was calculated from randomization, i.e. three months after high-dose therapy and approximately six months after start of induction therapy. The statistical analyses were performed in SPSS Statistics 18 for Windows (IBM Corporation, Somers, NY, USA).
Results
Patients and baseline characteristics Figure 1 shows the study profile. 403 patients were included at time of ASCT. A total of four patients were excluded due to non-secreting disease (2) or not fulfilling diagnostic criteria (2).
Of the remaining 399 patients, 29 were not randomized due to withdrawn consent (17), neuropathy (4), progressive disease before randomization(4), logistical reasons (2), early death (1) or severe infection (1). Of the remaining 370 patients, 187 were randomized to bortezomib consolidation therapy and 183 to the control group.
Baseline characteristics are shown in Table 1 . All variables were equally distributed between the two groups.
Completion of consolidation treatment
The median number of bortezomib injections received were 19 and the median given dose was 90 % (calculated as total given dose divided by total planned dose for each patient).
Survival
The overall median follow-up time was 38 months. The median progression-free survival (PFS) was prolonged for patients randomized to bortezomib consolidation (27 months vs 20 months, P = 0.05), figure 2A.
Patients achieving at least VGPR at any time experienced significant longer PFS compared to those who did not (28 months vs 16 months, P < 0.001) irrespective if the patient was randomized to bortezomib treatment or not, figure 2B. Beneficial effect of bortezomib For personal use only. on September 14, 2017. by guest www.bloodjournal.org From consolidation was only seen in patients not achieving at least VGPR after ASCT, figure 2C and 2D. Further, no difference in PFS was seen in patients being in ≥ VGPR at randomization compared to those improving their response to ≥ VGPR during the study, data not shown.
Since only 15 patients underwent a double ASCT no meaningful statistics could be calculated comparing single and double ASCT. No difference in PFS was seen for patients under the age of 60 years compared to those aged 60 or over, data not shown. After three years of follow up the overall survival was similar in both treatment groups, about 80%, figure 2E .
Response rate
The response rates at randomization 3 months after ASCT and best response during the study, calculated on an intention-to-treat-basis are presented in table 2. At randomization there was no difference in response rate between the groups, about 20% of all randomized patients had achieved CR/nCR and about 40% had achieved at least VGPR. Measured as best response achieved during the study, there was a difference with more bortezomib treated patients achieving at least VGPR (71% vs 57% P < 0.01) and a trend towards more patients achieving CR/nCR (45% vs 35 % P = 0.055). Improvement of response from PR to at least VGPR was also more common in patients receiving bortezomib consolidation (51 of 90 patients, 57% vs 32 out of 90, 36%, P = 0.007).
Toxicity
Sensory peripheral neuropathy was reported by 57 % of patients in the treatment group versus 24 % in the control group. Neuropathic pain was reported by 34 % and 12 % respectively. Sensory neuropathy > grade 2 on the CTC toxicity scale were experienced by 5 % of bortezomib treated patients versus 1 % for controls (P < 0.04), whereas neuropathic pain > grade 2 was experienced by 6 % versus 1 % (P < 0.006), figure 3. and platelet counts was less pronounced during the last four treatment cycles when bortezomib was given once weekly, figure 4.
Two cases of secondary primary malignancy were reported. One of the bortezomib treated patients developed a breast cancer and one patient in the control group developed a rectal cancer.
Health-related quality of life
Baseline questionnaires were available for 311 patients (84%). There were no significant differences in HRQOL score between the bortezomib group and the control group at baseline. After 8 weeks, there were statistically significant more fatigue and nausea/vomiting in the bortezomib group (P < 0.01). However, only the fatigue scale reached what we previously had set as a cut off for clinically relevant changes (6 points on a 0-100 scale) figure 5. There were no significant differences in HRQOL scores between the bortezomib group and the control group during the rest of the study period.
Discussion
This randomized, multicenter phase 3 trial in newly diagnosed myeloma patients showed that consolidation with bortezomib after ASCT did improve response and resulted in a statistical significant 7 month prolongation of PFS in bortezomib naïve patients. However, the study hypothesis of a 12 month prolongation of PFS was not confirmed. Our data indicates that the prolongation of PFS was mediated by an increased proportion of patients achieving an improvement in the quality of the response after bortezomib consolidation. Supporting this theory are the findings that the proportion of patients improving their grade of response was significantly higher for the treatment group and that the beneficial effect of bortezomib consolidation on PFS only was seen in patients not achieving at least VGPR after ASCT.
Finally, there was no difference in PFS for patients in ≥ VGPR after ASCT compared to those who achieved it later during the study.
No difference in OS was seen and this could be due to the fact that treatment at progression today is very effective and there are many treatment options. More patients in the control group did receive bortezomib containing combinations after first relapse, 48 versus 19. Apart from this there were small differences in second line therapy; a second ASCT was given to 17 of controls and 18 of patients receiving bortezomib consolidation, thalidomide 25 vs 27, lenalidomide 2 vs 9, chemotherapy combinations 10 vs 13 and radiation alone 10 vs 4. A landmark analysis starting at the time of relapse did not show any difference in estimated OS (4.0 years for controls versus 3.9 years for patients randomized to consolidation.
The role of consolidation and maintenance therapy is still unclear in myeloma therapy. The earliest experiences with chemotherapy were disappointing [16] [17] and the beneficial effect of corticosteroids as single drug maintenance 18 has been questioned. 19 Meta-analyses of interferon alfa have shown positive effect but at the cost of substantial tolerability problems. 20 Several studies have shown prolonged PFS and some even prolonged OS when thalidomide has been given as consolidation or maintenance after ASCT but with substantial toxicity, mainly neurological. 21 An interesting finding in the French study, IFM 99-02, is that the beneficial effect of thalidomide was only seen in patients achieving less than VGPR after ASCT. 22 Hence, the effect of thalidomide in the IFM study and of bortezomib in our study both seem to have been mediated by improving the degree of treatment response. In contrast, data from the British study, MRC IX, indicates that the effect of thalidomide given after ASCT has an effect of maintenance more than consolidation since the beneficial effect of thalidomide treatment did not differ due to response after ASCT. 23 Similar results were seen in 2 studies using lenalidomide as maintenance therapy after ASCT. [24] [25] Regardless of response after ASCT, this treatment approach seemed to be beneficial.
In recent years, several studies and meta-analyses indicate that achievement of complete response or at least very good partial response after ASCT is associated with a better outcome. [26] [27] These data supports the consolidation concept that is to apply a short course of treatment in order to reduce the number of residual tumour cells, which is shown by improved response status in patients with insufficient response after ASCT.
Consolidation with bortezomib after ASCT in combination with other drugs has been reported. In a recently published update, it was shown that the combination of bortezomib, thalidomide and dexamethasone is superior to thalidomide and dexamethasone alone, given as consolidation therapy after double ASCT. In this study, the same combinations are also used as initial therapy before ASCT. Using landmark analysis, the authors show that the superior results of the triplet combination over the double, are further improved by consolidation therapy and the beneficial effect is most evident in patients not achieving at least nCR after ASCT. 28 Even if it is dubious to compare results between studies, PFS in this Italian study is clearly longer than in our study, indicating that using different drugs in combination can be very effective as consolidation therapy. When our study was planned there were already data suggesting that corticosteroids did improve the effect of bortezomib in the relapse setting.
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However, since studies have implied that steroids do have an effect of their own given as consolidation therapy, we chose to give bortezomib as single drug, avoiding confusion about the results.
A weakness in the present study is that a repeat bone marrow examination not always was performed in order to confirm or reject CR. Patients with no measurable M-protein but for whom no bone marrow examination confirming CR was performed were downgraded to VGPR. This means that patients in the VGPR response category are a heterogeneous group containing both patients in true CR as well as patients with only a 90 % reduction of the original M protein. Unfortunately, cytogenetics was not available for more than a proportion of the patients. The reason for this was that FISH analysis was not standard at the time of the study in the Scandinavian countries and the study was performed also at smaller local hospitals with limited access to cytogenetic techniques.
An interesting and important finding that limits the difference between the two patient groups in this study is that about 17 % of the controls also improved their response. However, in the clinic it is not a rare finding that patients do improve their response up to one year after ASCT.
Some of the strengths of the study are that bortezomib was given as single drug, meaning that observed effects can only be attributed to this substance. Further, the QoL data shows that the additional therapy did not interfere with quality of life, which is very important when focusing on PFS. The risk of neurotoxicity might be reduced with a more restrictive dose-modification algorithm and our study showed that the haematological toxicity was more pronounced when bortezomib was given twice weekly compared to once weekly. The only significant differences in QoL, fatigue and nausea/vomiting after 7 weeks, did also disappear when the less frequent dose schedule was used. For elderly patients, it has already been suggested that administration of bortezomib once weekly makes the treatment more tolerable. 30 Also, modification of administration might be beneficial since there now are data showing that by administrating bortezomib subcutaneously instead of intravenously the incidence and severity of neuropathy can be significantly reduced 31 In conclusion, our study shows that consolidation with bortezomib after ASCT improves PFS and indicates that this is due to improvement of response. The treatment was well tolerated 
